Company Of The Day: Roche Holdings

October 19th, 2022 by Trefis Team
-2.65%
Downside
21.77
Market
21.19
Trefis
NWSA: News logo
NWSA
News

What?

Roche Holdings (OTCMKTS: RHHBY) Q3 2022 revenue declined 6% to CHF 14.74 billion ($14.8 billion).

Why?

Relevant Articles
  1. Down 10% This Year Is Coca-Cola Stock A Better Pick Over AbbVie?
  2. What’s Next For Nio Stock As Deliveries Continue To Fall Behind Rivals
  3. With 20% Gains In A Month Is Target A Better Pick Over FedEx Stock?
  4. Will Henry Schein Stock See Higher Levels After A 16% Fall This Year?
  5. Li Auto’s Delivery Momentum Shows No Signs Of Slowing. Is The Stock Undervalued At $36?
  6. Down 70% Since 2021, Can A Revival In Subscriber Growth Help WW International Stock Recover?

A decline in demand for Covid-19 diagnostics and treatments outweighed the gains that the company made with its hemophilia and multiple sclerosis drugs.

So What?

Roche stock was down by almost 1.5% in early trading on Tuesday although it recovered later in the day.

See Our Complete Analysis For Roche

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

 Returns Oct 2022
MTD [1]		 2022
YTD [1]		 2017-22
Total [2]
 RHHBY Return 1% -20% 44%
 S&P 500 Return 4% -22% 66%
 Trefis Multi-Strategy Portfolio 3% -24% 201%

[1] Month-to-date and year-to-date as of 10/19/2022
[2] Cumulative total returns since the end of 2016

 

Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates